Tuesday, January 09, 2024 12:10:22 AM
https://www.humanigen.com/subsidiaries
Regardless, it appears that he may be buying the equity one of them.
I need to point out that there is an Item 7.01 Regulation FD Disclosure which states, "The Company expects that holders of shares of the Company’s common stock will experience a complete or significant loss on their investment, depending on the outcome of the Chapter 11 Case." We pretty much did that, already.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465924000421/o152468k.htm
However, a long range plan is in place for Taran (Durrant's Therapeutic company) to pay "...$20 million, comprised of $2 million in cash at closing of the Transaction and up to $18 million in milestone payments in cash..." spread out over a 5 - 7 year time frame. This obviously indicates that the company anticipates to survive as a going concern.
I'm pointing out what has been filed. But at the same time, I think the concern will prove moot, as it appears to me that we are prepared to repeat our history, and issue a second recall of our loaned shares.
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM